Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd announced that their PromarkerEso blood test has shown high accuracy in diagnosing early stages of esophageal adenocarcinoma (EAC), a common form of esophageal cancer often caused by chronic acid reflux. This advancement could significantly improve early detection rates, offering a less invasive alternative to current diagnostic methods and potentially enhancing survival rates for patients, as EAC is often diagnosed too late for effective treatment.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing novel diagnostic tests. The company is known for its innovative solutions in the healthcare industry, particularly in creating blood tests that improve early detection and management of various diseases.
Average Trading Volume: 357,716
Technical Sentiment Signal: Sell
Current Market Cap: A$49.92M
Learn more about PIQ stock on TipRanks’ Stock Analysis page.